JP2023549849A - 血管性浮腫の予防および処置 - Google Patents

血管性浮腫の予防および処置 Download PDF

Info

Publication number
JP2023549849A
JP2023549849A JP2023528620A JP2023528620A JP2023549849A JP 2023549849 A JP2023549849 A JP 2023549849A JP 2023528620 A JP2023528620 A JP 2023528620A JP 2023528620 A JP2023528620 A JP 2023528620A JP 2023549849 A JP2023549849 A JP 2023549849A
Authority
JP
Japan
Prior art keywords
compound
solvate
pharmaceutically acceptable
acceptable salt
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023528620A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549849A5 (https=
Inventor
ルサージュ，アン
ルー，ペン
Original Assignee
ファルバリス ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファルバリス ゲーエムベーハー filed Critical ファルバリス ゲーエムベーハー
Publication of JP2023549849A publication Critical patent/JP2023549849A/ja
Publication of JP2023549849A5 publication Critical patent/JP2023549849A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023528620A 2020-11-12 2021-11-12 血管性浮腫の予防および処置 Pending JP2023549849A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20207273 2020-11-12
EP20207273.2 2020-11-12
PCT/EP2021/081493 WO2022101395A1 (en) 2020-11-12 2021-11-12 Prophylaxis and treatment of angioedema

Publications (2)

Publication Number Publication Date
JP2023549849A true JP2023549849A (ja) 2023-11-29
JP2023549849A5 JP2023549849A5 (https=) 2024-11-18

Family

ID=73401436

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023528620A Pending JP2023549849A (ja) 2020-11-12 2021-11-12 血管性浮腫の予防および処置

Country Status (12)

Country Link
US (1) US20230338358A1 (https=)
EP (1) EP4243824B1 (https=)
JP (1) JP2023549849A (https=)
KR (1) KR20230107269A (https=)
CN (1) CN116685353A (https=)
AU (1) AU2021376885A1 (https=)
CA (1) CA3198246A1 (https=)
ES (1) ES3061585T3 (https=)
IL (1) IL302887A (https=)
MX (1) MX2023005563A (https=)
WO (1) WO2022101395A1 (https=)
ZA (1) ZA202305122B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3062067T3 (en) * 2022-03-25 2026-04-08 Pharvaris Gmbh Solid composition comprising solubilised bradykinin b2-receptor antagonists
TW202345810A (zh) * 2022-03-25 2023-12-01 瑞士商帕法瑞斯有限責任公司 包含緩激肽ｂ２受體拮抗劑之固態延長釋放組成物
WO2025037920A1 (ko) 2023-08-16 2025-02-20 주식회사 엘지화학 수지 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080249076A1 (en) * 2003-12-03 2008-10-09 Lifecycle Pharma A/S Pharmaceutical Compositions Comprising Danazol
JP2017145262A (ja) * 2009-12-04 2017-08-24 インターミューン， インコーポレイテッド ピルフェニドン療法を施す方法
WO2019101906A1 (en) * 2017-11-24 2019-05-31 Pharvaris B.V. Novel bradykinin b2 receptor antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080249076A1 (en) * 2003-12-03 2008-10-09 Lifecycle Pharma A/S Pharmaceutical Compositions Comprising Danazol
JP2017145262A (ja) * 2009-12-04 2017-08-24 インターミューン， インコーポレイテッド ピルフェニドン療法を施す方法
WO2019101906A1 (en) * 2017-11-24 2019-05-31 Pharvaris B.V. Novel bradykinin b2 receptor antagonists

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"ボンゾール錠２００ｍｇ", 医薬品インタビューフォーム, vol. 第９版, JPN6025043168, ISSN: 0005839026 *
FRONTIERS IN PHARMACOLOGY, vol. 11, no. 916, JPN6025043166, 19 June 2020 (2020-06-19), pages 1 - 14, ISSN: 0005712062 *
日本耳鼻咽喉科学会会報, vol. 122, no. 11, JPN6025043167, 2019, pages 1457 - 1459, ISSN: 0005839025 *

Also Published As

Publication number Publication date
EP4243824B1 (en) 2025-12-24
MX2023005563A (es) 2023-09-11
ES3061585T3 (en) 2026-04-06
WO2022101395A1 (en) 2022-05-19
ZA202305122B (en) 2024-08-28
CN116685353A (zh) 2023-09-01
CA3198246A1 (en) 2022-05-19
IL302887A (en) 2023-07-01
KR20230107269A (ko) 2023-07-14
EP4243824A1 (en) 2023-09-20
AU2021376885A1 (en) 2023-06-08
US20230338358A1 (en) 2023-10-26
EP4243824C0 (en) 2025-12-24

Similar Documents

Publication Publication Date Title
EP4003327B1 (en) Compounds for use in the treatment of paroxysmal nocturnal haemoglobinuria (pnh)
US20180161314A1 (en) Methods for Treating Hyperuricemia and Related Diseases
JP2023549849A (ja) 血管性浮腫の予防および処置
US10806735B2 (en) Use of neutrophil elastase inhibitors in liver disease
EP4110326B1 (en) Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
US10806792B2 (en) Itraconazole compositions and dosage forms, and methods of using the same
US20230404971A1 (en) Combination Comprising Abemaciclib and 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-Fluoropropyl)Pyrrolidin-3-yl]Oxyphenyl]-8,9-Dihydro-7H-Benzo[7]Annulene-2-Carboxylic Acid
US11554106B2 (en) Prevention of the risks associated with drug-induced QT interval prolongation by using a specific inhibitor of the production of ROS of miochondrial origin
EP4322941A1 (en) Combination comprising ribociclib and amcenestrant
JP6145946B2 (ja) 併用ａｌｓ療法
CN108778266A (zh) 包含二高γ亚麻酸（DGLA）的医药组合物和其用途
Donadille et al. Management of Cushing’s syndrome due to ectopic adrenocorticotropin secretion with 1, ortho-1, para′-dichloro-diphenyl-dichloro-ethane: findings in 23 patients from a single center
RU2758386C2 (ru) Новая вспомогательная терапия для применения в способе лечения рака простаты
Jessa et al. The effect of omeprazole on the pharmacokinetics of metronidazole and hydroxymetronidazole in human plasma, saliva and gastric juice
HK40099091A (en) Prophylaxis and treatment of angioedema
HK40099091B (en) Prophylaxis and treatment of angioedema
Suh et al. Efficacy and tolerability of amlodipine camsylate/losartan 5/100-mg versus losartan/hydrochlorothiazide 100/12.5-mg fixed-dose combination in hypertensive patients nonresponsive to losartan 100-mg monotherapy
KR20240019265A (ko) Mmp-12 억제제의 안전한 투여
Fanouriakis et al. AB0442 Real-life experience with belimumab in systemic lupus erythematosus (SLE): control of disease activity and flares in a multicenter cohort
Zonneveld Psoriasis. Present therapies and new developments
NZ619924B2 (en) Combination als therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230522

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20230522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241108

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251014

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251021

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260323

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260414